AN2 Therapeutics (ANTX) Liabilities and Shareholders Equity (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $87.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 7.56% year-over-year to $87.5 million; the TTM figure through Mar 2026 stood at $292.5 million (down 22.94% YoY), while the FY2025 annual figure was $62.0 million, down 32.73% from the prior year.
• Liabilities and Shareholders Equity grew to $87.5 million in Q1 2026 per ANTX's latest filing, from $62.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $153.8 million in Q3 2023 and bottomed at $62.0 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $101.7 million across 5 years, with a median of $98.9 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 57.02% — and 2024, when it tumbled 36.49%.
• AN2 Therapeutics' Liabilities and Shareholders Equity stood at $102.6 million in 2022, then soared by 35.28% to $138.7 million in 2023, then plunged by 33.63% to $92.1 million in 2024, then sank by 32.73% to $62.0 million in 2025, then surged by 41.23% to $87.5 million in 2026.
• Business Quant data shows ANTX's Liabilities and Shareholders Equity at $87.5 million in Q1 2026, $62.0 million in Q4 2025, and $67.2 million in Q3 2025.